ERBB2 and triple-negative breast carcinoma: Although immune checkpoint inhibitors have marked clinical advantages in various tumor types, their efficacy in Triple-Negative Breast Cancer (TNBC) and Human Epidermal Growth Factor Receptor 2 positive (HER2+) patients remains limited.